The PTP1B Inhibitor Trodusquemine (MSI-1436) Improves Glucose Uptake in Equine Metabolic Syndrome Affected Liver through Anti-Inflammatory and Antifibrotic Activity.
Lynda BourebabaAnna Serwotka-SuszczakNabila BourebabaMagdalena ZyzakKrzysztof MaryczPublished in: International journal of inflammation (2023)
Taken together, the presented data suggest that the PTP1B inhibition strategy and the use of its specific inhibitor MSI-1436 represents a promising option for the improvement of liver tissue integrity and homeostasis in the course of EMS and adds more insights for ongoing clinical trials for human MetS management.
Keyphrases
- metabolic syndrome
- clinical trial
- anti inflammatory
- endothelial cells
- electronic health record
- induced pluripotent stem cells
- insulin resistance
- big data
- randomized controlled trial
- blood glucose
- pluripotent stem cells
- blood pressure
- adipose tissue
- phase ii
- deep learning
- cardiovascular risk factors
- phase iii
- data analysis